Evox Therapeutics

Executive Summary

Evox Therapeutics is a UK-based preclinical biotech pioneering exosome-based delivery of genetic medicines to the brain. Leveraging a proprietary exosome platform with a strong safety track record and enhanced brain access, the company aims to overcome the blood-brain barrier for gene therapies targeting severe neurodegenerative diseases. Founded in 2016 and operating in Oxford, Evox focuses on scalable, safer, and more effective treatments by combining exosome technology with gene editors. The company is currently advancing its lead programs toward the clinic, with a potential to address significant unmet needs in CNS disorders. While still in early stages, the platform's versatility and promising preclinical data position Evox as an attractive player in the genetic medicine space, though execution risks and regulatory hurdles remain.

Upcoming Catalysts (preview)

• Q4 2026IND/CTA filing for lead exosome-based gene therapy program60% success
• Q2 2026Presentation of preclinical in vivo efficacy data at a major conference (e.g., ASGCT)80% success
• Q3 2026Announcement of a strategic partnership or licensing deal with a large pharma for CNS exosome delivery30% success